Core Points - The company announced a cash dividend distribution of 0.10 RMB per share, totaling approximately 9.36 million RMB based on a total share capital of 93,567,699 shares [1] - The profit distribution plan was approved at the annual shareholders' meeting held on May 15, 2025 [1] - The cash dividend will be distributed to shareholders registered by the close of trading on the Shanghai Stock Exchange on the record date [1] Dividend Distribution Details - The cash dividend distribution will be handled by China Securities Depository and Clearing Corporation Limited Shanghai Branch for shareholders who have completed designated transactions [1] - Shareholders who have not completed designated transactions will have their dividends held by China Securities Depository and Clearing Corporation Limited until they complete the necessary transactions [1] - Specific tax implications for individual shareholders based on their holding period are outlined, with dividends being subject to different tax treatments depending on the duration of shareholding [3][4] Taxation Information - Individual shareholders holding shares for over one year will not be subject to personal income tax on dividends, while those holding for one year or less will have taxes calculated upon the transfer of shares [3] - Qualified Foreign Institutional Investors (QFIIs) will have a withholding tax of 10% applied to their dividends, resulting in a net dividend of 0.09 RMB per share [4] - Hong Kong investors holding shares through the Shanghai-Hong Kong Stock Connect will also face a 10% withholding tax, with dividends distributed in RMB [5]

证券代码：688393 证券简称：安必平 公告编号：2025-025 广州安必平医药科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本93,567,699股为基数，每股派发现 金红利0.10元（含税），共计派发现金红利9,356,769.90元。 是否涉及差异化分红送转：否 每股分配比例 每股现金红利0.10元 相关日期 1. 发放年度：2024年年度 2. 分派对象： 三、 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/5/28 | 2025/5/29 | 2025/5/29 | | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | ...

证券代码：688393 证券简称：安必平 公告编号：2025-024 二、监事会会议审议情况 公司已于 2025 年 5 月 15 日召开 2024 年年度股东大会，审议通过了《关于 补选非职工代表监事的议案》，同意补选黄凯立先生为公司第四届监事会非职工 代表监事，任期自 2024 年年度股东大会审议通过之日起至第四届监事会任期届 满之日止。 为保障公司第四届监事会各项工作的顺利开展，公司全体监事一致同意选 举职工代表监事金信汝女士为公司第四届监事会主席，任期自本次监事会审议 通过之日起至第四届监事会任期届满之日止。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 特此公告。 广州安必平医药科技股份有限公司 第四届监事会第八次会议决议暨 选举第四届监事会主席的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 广州安必平医药科技股份有限公司(以下简称"公司")第四届监事会第八 次会议于 2025 年 5 月 19 日在公司会议室以现场方式召开。本次会议的通知于 共同推举职工代表监事金信汝女 ...

证券代码：688393 证券简称：安必平 公告编号：2025-024 广州安必平医药科技股份有限公司 第四届监事会第八次会议决议暨 选举第四届监事会主席的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 特此公告。 广州安必平医药科技股份有限公司监事会 2025 年 5 月 20 日 一、监事会会议召开情况 广州安必平医药科技股份有限公司(以下简称"公司")第四届监事会第八 次会议于 2025 年 5 月 19 日在公司会议室以现场方式召开。本次会议的通知于 2025 年 5 月 16 日以电子邮件方式送达至公司全体监事。本次会议由全体监事 共同推举职工代表监事金信汝女士主持，会议应参与表决的监事 3 名,实际参与 表决的监事 3 名。本次会议的召集、召开符合相关法律、法规、规则及《公司 章程》的有关规定。 二、监事会会议审议情况 1、审议通过《关于选举第四届监事会监事会主席的议案》： 公司已于 2025 年 5 月 15 日召开 2024 年年度股东大会，审议通 ...

Core Insights - The aging population, scarcity of grassroots medical resources, and uneven distribution of quality medical resources are driving the rapid integration and application of AI technology in the healthcare sector [2] - AI medical technology is expected to reconstruct the medical value chain, creating a new model for equitable access to medical resources [5] - The domestic AI medical market is projected to reach 159.8 billion yuan by 2028, with a compound annual growth rate of 10.5% from 2022 to 2028 [7] Industry Overview - The aging population in China is expected to reach 310 million by the end of 2024, accounting for 22% of the total population, and is projected to exceed 400 million by 2035, surpassing 30% [2] - Grassroots medical institutions account for 94.9% of all medical institutions in China but only handle 51.8% of the total medical services, indicating a mismatch in resource utilization and service quality [2] - AI technology is being rapidly integrated across various medical processes, including imaging diagnosis, surgical assistance, drug development, and intelligent management [2] AI Medical Technology - AI medical technology enhances the quality and efficiency of healthcare services by providing intelligent management and optimization of medical processes [3] - AI medical devices can be categorized into two types: those that include hardware (e.g., diagnostic analysis systems, robots) and those that operate as standalone software [3] - The advantages of AI in healthcare include high efficiency, accuracy, and low misdiagnosis rates, which can significantly improve diagnostic processes and treatment timelines [4] Market Potential - The AI medical market is expanding rapidly, with significant applications in drug and vaccine development, medical imaging analysis, smart hospital management, and genomics research [7] - AI applications in in-vitro diagnostics are expected to grow at a compound annual growth rate of 26.1% by 2028 [17] Company Profiles - Mindray Medical (300760) has a comprehensive product line in life information and support, in vitro diagnostics, and medical imaging, with a projected revenue of 36.725 billion yuan in 2024, a 5.14% increase year-on-year [10] - United Imaging (688271) focuses on medical imaging equipment and has been investing in AI since 2017, with a projected revenue of 10.3 billion yuan in 2024, a 9.73% decrease year-on-year [14] - BGI Genomics (300676) specializes in genomic testing services and is expected to generate 3.867 billion yuan in revenue in 2024, an 11.10% decrease year-on-year [19] - Yuyue Medical (002223) is a leading provider of medical devices, with a projected revenue of 7.566 billion yuan in 2024, a 5.09% decrease year-on-year [23] - Kefu Medical (301087) focuses on home medical devices and is expected to achieve 2.983 billion yuan in revenue in 2024, a 4.53% increase year-on-year [25]

Group 1 - The board of directors guarantees that the announcement contains no false records, misleading statements, or significant omissions, and assumes legal responsibility for its authenticity, accuracy, and completeness [1] - The shareholder meeting was held at the company's conference room located at No. 2, Kexin Street, Huangpu District, Guangzhou [2] - The voting method for the meeting was conducted both on-site and online, complying with the Company Law and the company's articles of association [3] Group 2 - The meeting was convened by the board of directors and chaired by Mr. Cai Xiangting, the chairman [5] - All 9 current directors and 3 current supervisors attended the meeting, along with the board secretary and other senior executives [5] - The meeting approved several proposals, including the 2024 annual report and its summary, the 2024 board work report, and the 2024 profit distribution plan [6][6][6] Group 3 - The meeting also approved the reappointment of the accounting firm and the financial settlement report for 2024 [6][6] - A proposal for the board to issue shares to specific targets through a simplified procedure was also approved [6] - The legal proceedings of the shareholder meeting were confirmed to comply with the Company Law and relevant regulations, ensuring the legality and validity of the meeting's proceedings and results [7]

律师：郭梦玥、陈诗雨 | 证券代码：688393 证券简称：安必平 | 公告编号：2025-023 | | | | | --- | --- | --- | --- | --- | | 广州安必平医药科技股份有限公司 | | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | | | | | | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | 重要内容提示： | | | | | | ? 本次会议是否有被否决议案：无 | | | | | | 一、 会议召开和出席情况 | | | | | | （一） 股东大会召开的时间：2025 年 5 月 | 15 日 | | | | | （二） | 2 股东大会召开的地点：广州市黄埔区科信街 号公司会议室 | | | | | （三） | 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 | | | | | 其持有表决权数量的情况： | | | | | | 普通股股东人数 | 29 | | | | | 普通股股东所持有表决权数量 | 32,883,491 | | | | | 例（%） | ...

言達律師事務所 INDIAL LAW FIRM 中国深圳市福田区益田路 6001 号太平金融大厦 11、12 楼 邮编: 518038 11-12/F, TAIPING FINANCE TOWER, YITIAN ROAD 6001, FUTIAN DISTRICT, SHENZHEN, P.R. CHINA 电话(Tel):(0755)88265288 传真(Fax):(0755)88265537 电子邮件(E-mail): info@sundiallawfirm.com 网址(Website): www.sundiallawfirm.com 广东信达律师事务所 关于广州安必平医药科技股份有限公司 2024 年年度股东大会的法律意见书 股东大会法律意见书 信达科会字(2025)第 023 号 致:广州安必平医药科技股份有限公司 广东信达律师事务所(以下简称"信达")接受广州安必平医药科技股份有 限公司(以下简称"公司")的委托,指派信达律师出席公司 2024年年度股东 大会(以下简称"本次股东大会"),对本次股东大会的合法性进行见证,并出 具《广东信达律师事务所关于广州安必平医药科技股份有限公司 2024 ...

证券代码：688393 证券简称：安必平 公告编号：2025-023 广州安必平医药科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 15 日 （二） 股东大会召开的地点：广州市黄埔区科信街 2 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 29 | | --- | --- | | 普通股股东人数 | 29 | | 2、出席会议的股东所持有的表决权数量 | 32,883,491 | | 普通股股东所持有表决权数量 | 32,883,491 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 35.1441 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 35.1441 | 审议结果：通过 （四） ...

Investment Rating - The report maintains an investment rating of "Outperform the Market" for the medical device industry [2]. Core Insights - The report emphasizes that AI in healthcare is restructuring diagnostic and treatment processes, creating investment opportunities driven by efficiency and market growth. The global healthcare sector faces challenges such as aging populations and uneven distribution of medical resources, which AI can address by optimizing the healthcare value chain and promoting equitable access to medical resources [5][6]. Summary by Sections 1. AI Healthcare Development Environment - The domestic AI healthcare development environment is mature, supported by data resources and services that enhance algorithm accuracy and generalization [11]. - AI technology is breaking the uneven distribution of medical resources, addressing the growing demand for healthcare services due to an aging population [18][19]. 2. AI Medical Imaging - AI medical imaging is the most mature application of AI in healthcare, with a complete ecosystem covering various imaging modalities such as CT, MRI, and X-ray. The market for AI medical imaging in China is projected to reach 6.17 billion yuan by 2025 [5][39]. - Companies like Mindray and United Imaging are leveraging hardware advantages to build "device + AI" ecosystems, while pure AI companies focus on lesion recognition and cross-disease generalization capabilities [5][39]. 3. AI In Vitro Diagnostics - The AI in vitro diagnostics market is rapidly growing, with applications in hematology, microbiology, and pathology. Companies like BGI and Anbiping are innovating with AI-driven solutions to enhance diagnostic efficiency [5][6]. 4. AI Wearable Devices - AI wearable devices are transforming health management by providing real-time monitoring and data analysis, becoming essential for chronic disease management. The market for smart wearable devices in China is expected to exceed 15 billion yuan in 2023 and reach 33 billion yuan by 2026, with a compound annual growth rate of 18.1% [6]. 5. Investment Recommendations - The report suggests that the industry is poised for multidimensional development, transitioning from scale expansion to higher-level growth. It highlights long-term investment opportunities in leading companies like Mindray, United Imaging, Yuyue Medical, and Kefu Medical, which are early adopters of AI healthcare solutions [6].